Prescribing information and adverse event reporting information can be accessed using the PI & AE button at the side.

Browse events

See below for the list of upcoming events where Idorsia will be participating.
Event Type Radio Filter

Pulse LIVE Glasgow

4 CPD hours. Pulse LIVE Glasgow takes place at Crowne Plaza Glasgow on Tuesday 29 September 2026: a free, CPD-accredited one-day event designed exclusively for UK GPs. The agenda is...

Location:

Glasgow

Date and Time:

29 September 2026

Event type:

In-person

UK-DA-01586 | Date of preparation: July 2026

Webinar

Nocturia in sleep disorders: management options in patients at risk of falls

The penultimate webinar in our 2026 Beyond sleepless nights: managing chronic insomnia in adults series, in collaboration with MIMS Learning. Dr Tim Mercer, GP Partner, based in Wirral, reviews the management...

Date and Time:

6 October 2026 - 19:00-20:00

UK-DA-01523 | Date of preparation: July 2026

Best Practice

Up to 12 CPD points. Best Practice takes place at the NEC Birmingham on Wednesday 7 and Thursday 8 October 2026: a free, CPD-accredited two-day event for UK primary care...

Location:

NEC Birmingham

Date and Time:

7-8 October 2026

Event type:

In-person

UK-DA-01588 | Date of preparation: August 2026

RCGP Annual Conference 2026

The RCGP Annual Conference and Exhibition takes place at the SEC Glasgow on Thursday 29 & Friday 30 October 2026: a must-attend two-day event for GPs and the primary care...

Location:

SEC Glasgow

Date and Time:

29-30 October 2026

Event type:

In-person

UK-DA-01589 | Date of preparation: July 2026

Webinar

2026 series overview: turning learning into improved patient outcomes

The final webinar in our 2026 Beyond sleepless nights: managing chronic insomnia in adults series, in collaboration with MIMS Learning. In this final webinar of our 2026 series with MIMS Learning, Dr...

Date and Time:

10 November 2026 - 19:00-20:00

UK-DA-01524 | Date of preparation: July 2026

Gain access to resources on chronic insomnia

Subscribe to get priority updates  and access to videos, data and patient resources, plus details about us and our offerings.

Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.

Discover how QUVIVIQ™ ▼ (daridorexant) is different to other hypnotics1,2:

Works differently1,2

Is taken differently1,3

Is experienced differently1,4

Book an appointment

One of our product specialists would be happy to answer your questions.

QUVIVIQ™ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1

References

1 – QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics. 

2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.

3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated May 2025. Accessed June 2025.

4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.

This information is intended for UK healthcare professionals.

Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.

UK-DA-00739 | Date of preparation: July 2025

Copyright © 2026 Idorsia Pharmaceuticals Ltd
Create an account
Access our in-depth e-learning resources on chronic insomnia
Title *
First name *
Last name *
Professional email *
Password *
Specialty *
Professional registration number *

You already have an account? 

Gain access to resources on chronic insomnia​

Register to get access to:

Welcome back!

Please complete the form below to sign in.

You don’t have an account? 

Table of Contents

You are now entering
pro.idorsia.uk

You are being redirected to our partner’s website pro.idorsia.uk.       The content of this website contains promotional information for UK healthcare professionals and is managed by
Idorsia Pharmaceuticals UK Ltd.

UK-DA-01463 | Date of preparation: April 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd

Your resource is ready to download.

Providing your details is optional, but enables us to share future updates and resources that may be of interest to you.

Download will open in a new window.

Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.

You are now leaving
pro.idorsia.uk

You will now be redirected to an independent third party site that is maintained outside of this website, where all Idorsia Pharmaceuticals Ltd UK’s medicines can be found: the electronic Medicines Compendium (eMC)

UK-DA-00439 | Date of preparation: February 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd

You are now leaving
pro.idorsia.uk

You are now leaving pro.idorsia.uk. You will now be redirected to an independent third-party site that is maintained outside of this website.

You are now leaving hcpukportalstg.wpenginepowered.com. The linked website provides helpful information if you are having trouble sleeping. It is neither owned or controlled by Idorsia Pharmaceuticals Ltd. Idorsia accepts no responsibility for the content or services of the linked site.

UK-DA-00445 | Date of preparation: Februrary 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd

Confirming your contact information and preferences means that you agree that we, Idorsia, manage your personal data in our Client Relationship Management system to document, customise, plan, and conduct our interactions with you and, to analyse and segment your interactions, interests, preferences, and scientific activities in order to interact with you in a way we think is most relevant to you.

It also means that you agree that we will send you Idorsia standard or personalised medical, company or product related information and material via email based on your choices and on what we think is of interest to you. You further consent that we process your personal data for this.

For more information about us, our processing of your personal data and your rights, please see our Privacy Notice.

Welcome to the Idorsia UK
Healthcare Professional Portal

This information is intended for UK Healthcare Professionals only.

By entering this site you are confirming that you are a UK Healthcare Professional.

UK-DA-00217 | Date of preparation: February 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd